Shire/Takeda Pharmaceutical’s lifitegrast for treating dry eye disease is among the four new additions to the Pink Sheet's regularly updated list of products that are being evaluated by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) under the EU's centralized authorization procedure. The other three new additions are AstraZeneca’s triple combination therapy, budesonide/glycopyrronium/formoterol (fumarate dihydrate) (PT010), for chronic obstructive pulmonary disease, and two generic drugs: arsenic trioxide, an antineoplastic medicine, and dexmedetomidine, a psycholeptic.
The information in our list is based on the list of new medicines under review at the EMA that the...







